Home > Formulary : Paediatric > Recent Decisions > 2021 >
Decisions 16th March 2021
At the meeting on the 16th March the following decisions were agreed
New Drug Requests
Approved
OralVac®(TLS Red)
- for grass, tree pollen and house dust mite allergy, for use by immunology only, commissioned by NHS England
Potassium Chloride 600mg (8mmol) modified release tablets (TLS Red)
- for short courses for patients where other preparations are not suitable or tolerated
Potassium Chloride 600mg (8mmol) modified release tablets (TLS Amber, no SCP)
- for long term treatment courses for patients where other preparations are not suitable or tolerated
Qlaira ® (estradiol valerate, dienogest) (TLS Amber, no SCP)
- as an option for patients with premature ovarian insufficiency requiring contraception and HRT cover where standard oral contraceptives are not suitable and patients have completed puberty.
- JFG did not approve this as a standard contraception for other patients outside of this cohort
Shared Care Protocols/TLS changes
New SCPs:
Nil
Updated SCPs:
Nil
Other Formulary Decisions:
- Aminophylline (Phyllocontin brand) removed as discontinued. Parental aminophylline changed from TLS Green to TLS Red
- Ulipristal (Esmya) changed from TLS Amber to TLS Red and SCP removed due to MHRA alert and formulary review required
- Hyoscine hydrobromide patches changed from TLS Green to TLS Amber no SCP and agreement to amend Botox Pathway to reflect this TLS change
- Melatonin review of current formulary and non formulary indications will commence this year in conjunction with all relevant parties across the BNSSG system